Coya Therapeutics reported its QQ4 2024 results with a continuation of large operating expenditures and negative profitability, but a solid cash position driven by financing activities. Revenue for the quarter was $1.95 million, with a gross loss of $4.89 million, reflecting ongoing heavy investment in R&D and general corporate activities as the company advances its Treg-focused pipeline. On a YoY basis, revenue declined by approximately 99.97%, and gross profit declined by about 100.08%, underscoring the early-stage nature of the business and reliance on fundraising rather than product sales at this stage. Despite the loss-making profile, the balance sheet shows meaningful liquidity (cash and cash equivalents of about $38.3 million) and no (gross) debt, supported by financing activities that added roughly $9.7 million in the period and led to a net cash increase of about $7.3 million. The company’s pipeline spans COYA 101 (autologous Treg product in ALS Phase 2a), COYA 301 (Treg-enhancing biologic in IND-enabling studies for Frontotemporal Dementia), COYA 302 (biologic combination to enhance Treg function and suppress inflammatory cells), and COYA 201 (preclinical allogeneic Treg exosome candidate), with discovery-stage COYA 206. Near-term catalysts will likely hinge on clinical updates and any advancement of IND-enabling studies, licensing discussions, or additional financing to sustain long-cycle R&D. Overall, the investment thesis remains highly contingent on clinical milestones and the potential to translate biology into meaningful patient outcomes, balanced against substantial ongoing operating losses and potential dilution.